Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.

You must read this new presentation from Porter Stansberry.

John Leite Biography and Net Worth

Chief Commercial Officer, CLIA Business of Veracyte

John Leite is Chief Commercial Officer, CLIA Business at Veracyte. In this role, Dr. Leite leads commercial operations for Veracyte’s diagnostic tests that are performed in the company’s CLIA laboratories. This includes market development, product marketing, reimbursement and sales. Dr. Leite joined Veracyte in September 2022, bringing with him deep diagnostics industry leadership experience. Previously, he served as Chief Business Officer for InterVenn Biosciences, a private-stage diagnostics company, where he was responsible for the company’s commercial, partnership and market access strategy. Prior to that, he held leadership positions at Illumina from 2014 to 2020, where he initially served as Vice President, Oncology, Market Development and Product Development, and then as Vice President, Clinical Business Development. Prior to Illumina, he was Vice President of Commercial Strategy and Market Access at Genoptix Medical Laboratories. Dr. Leite holds a B.S. in Biochemistry from Rutgers University and a Ph.D. in Biochemistry and Molecular Genetics from the University of Pittsburgh School of Medicine. In addition, he completed post-doctoral work as a National Research Service Award Fellow at the California Institute of Technology.

What is John Leite's net worth?: The estimated net worth of John Leite is at least $3.36 million as of September 4th, 2024. Mr. Leite owns 76,174 shares of Veracyte stock worth more than $3,360,797 as of December 3rd. This net worth estimate does not reflect any other assets that Mr. Leite may own. Additionally, Mr. Leite receives an annual salary of $1,530,000.00 as Chief Commercial Officer, CLIA Business at Veracyte. Learn More about John Leite's net worth.
How old is John Leite?: Mr. Leite is currently 52 years old. There are 6 older executives and no younger executives at Veracyte. The oldest executive at Veracyte is Dr. Phillip G. Febbo M.D., Chief Scientific & Medical Officer, who is 58 years old. Learn More on John Leite's age.
What is John Leite's salary?: As the Chief Commercial Officer, CLIA Business of Veracyte, Inc., Mr. Leite earns $1,530,000.00 per year. The highest earning executive at Veracyte is Mr. Marc A. Stapley, CEO & Director, who commands a salary of $1,550,000.00 per year. Learn More on John Leite's salary.
How do I contact John Leite?: The corporate mailing address for Mr. Leite and other Veracyte executives is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. Veracyte can also be reached via phone at (650) 243-6300 and via email at [email protected]. Learn More on John Leite's contact information.
Has John Leite been buying or selling shares of Veracyte?: John Leite has not been actively trading shares of Veracyte during the past quarter. Most recently, John Leite sold 5,479 shares of the business's stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $29.78, for a transaction totalling $163,164.62. Following the completion of the sale, the insider now directly owns 76,174 shares of the company's stock, valued at $2,268,461.72. Learn More on John Leite's trading history.
Who are Veracyte's active insiders?: Veracyte's insider roster includes Bonnie Anderson (Insider), Muna Bhanji (Director), Rebecca Chambers (Exec. VP & CFO ), Karin Eastham (Director), Jens Holstein (Director), Evan Jones (Director), Giulia Kennedy (Insider), John Leite (Chief Commercial Officer, CLIA Business), and Marc Stapley (CEO & Director ). Learn More on Veracyte's active insiders.
Are insiders buying or selling shares of Veracyte?: In the last year, insiders at the biotechnology company sold shares 12 times. They sold a total of 68,859 shares worth more than $1,995,245.65. The most recent insider tranaction occured on November, 27th when CAO Jonathan Wygant sold 5,032 shares worth more than $215,822.48. Insiders at Veracyte own 1.3% of the company. Learn More about insider trades at Veracyte.
Information on this page was last updated on 11/27/2024.

John Leite Insider Trading History at Veracyte

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/4/2024	Sell	5,479	$29.78	$163,164.62	76,174
7/16/2024	Sell	1,277	$25.00	$31,925.00	82,968

John Leite Buying and Selling Activity at Veracyte

Veracyte Company Overview

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Today's Range

Now: $43.26

$42.64

$43.77

50 Day Range

MA: $35.90

$31.92

$44.12

2 Week Range

Now: $43.26

$18.61

$44.45

Volume

171,549 shs

Average Volume

769,506 shs

Market Capitalization

$3.35 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.69

This company will win the AI race

From Porter & Company | Ad

You must read this new presentation from Porter Stansberry.

John Leite Biography and Net Worth

What is John Leite's net worth?

How old is John Leite?

What is John Leite's salary?

How do I contact John Leite?

Has John Leite been buying or selling shares of Veracyte?

Who are Veracyte's active insiders?

Are insiders buying or selling shares of Veracyte?